Wattle Health Australia Ltd shares surge higher again

The Wattle Health Australia Ltd (ASX: WHA) share price has pushed higher again in morning trade.

At the time of writing the infant formula and baby food company’s shares are up 8% to $2.32.

What happened?

This morning the company advised that it has received its first order for its 100% natural baby food range from Vasudevan and Sons Exim Private Limited in India.

The order was made after the company’s products met India’s strict importation criteria.

According to the release, management believes this order will open the door for Wattle Health to compete in one of the most populated areas in the world where almost half the population are under the age of 25.

Furthermore, management believes this deal complements its aim of expanding its product portfolio and distribution network in both domestic and international markets as a way of reducing its overall risk profile and the reliance on one particular product or market.

I feel this is management’s way of reminding investors that it isn’t a one-trick pony. After all, investor attention is focused almost entirely on its infant formula range and the prospect of it competing against A2 Milk Company Ltd (ASX: A2M) and Bellamy’s Australia Ltd (ASX: BAL) in the lucrative China market.

Should you invest?

While this is a positive development, it is hard to put a value on it as no financial terms were revealed today.

In light of this, I think investors ought to put Wattle Health on their watchlists but hold off an investment until sales data is provided.

With so much growth already built into its share price, I believe an investment carries a lot of risk at this point. While I’m hopeful that the company will more than justify its market capitalisation one day, there is no guarantee that it will.

In the meantime, investors may want to consider one of these exciting growth shares.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.